Revenue and profits rose sharply year-over-year, led by machinery and cost reductions, with net income up 90.4%. Full-year guidance is unchanged, and the dividend forecast was raised. External risks and pharmaceutical pricing pressures remain.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.